Skip to main content
Erschienen in: Hepatology International 2/2021

03.02.2021 | Original Article

Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study

verfasst von: Lei Liang, Bing Quan, Han Wu, Yong-Kang Diao, Jie Li, Ting-Hao Chen, Yao-Ming Zhang, Ya-Hao Zhou, Wan-Guang Zhang, Hong Wang, Matteo Serenari, Matteo Cescon, Myron Schwartz, Yong-Yi Zeng, Ying-Jian Liang, Hang-Dong Jia, Hao Xing, Chao Li, Ming-Da Wang, Wen-Tao Yan, Wan-Yuan Chen, Wan Yee Lau, Cheng-Wu Zhang, Timothy M. Pawlik, Dong-Sheng Huang, Feng Shen, Tian Yang

Erschienen in: Hepatology International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Evidence-based decision-making is critical to optimize the benefits and mitigate futility associated with surgery for patients with malignancies. Untreated hepatocellular carcinoma (HCC) has a median survival of only 6 months. The objective was to develop and validate an individualized patient-specific tool to predict preoperatively the benefit of surgery to provide a survival benefit of at least 6 months following resection.

Methods

Using an international multicenter database, patients who underwent curative-intent liver resection for HCC from 2008 to 2017 were identified. Using random assignment, two-thirds of patients were assigned to a training cohort with the remaining one-third assigned to the validation cohort. Independent predictors of postoperative death within 6 months after surgery for HCC were identified and used to construct a nomogram model with a corresponding online calculator. The predictive accuracy of the calculator was assessed using C-index and calibration curves.

Results

Independent factors associated with death within 6 months of surgery included age, Child–Pugh grading, portal hypertension, alpha-fetoprotein level, tumor rupture, tumor size, tumor number and gross vascular invasion. A nomogram that incorporated these factors demonstrated excellent calibration and good performance in both the training and validation cohorts (C-indexes: 0.802 and 0.798). The nomogram also performed better than four other commonly-used HCC staging systems (C-indexes: 0.800 vs. 0.542–0.748).

Conclusions

An easy-to-use online prediction calculator was able to identify patients at highest risk of death within 6 months of surgery for HCC. The proposed online calculator may help guide surgical decision-making to avoid futile surgery for patients with HCC.
Literatur
1.
Zurück zum Zitat Wilson A, Ronnekleiv-Kelly SM, Pawlik TM. Regret in surgical decision making: a systematic review of patient and physician perspectives. World J Surg 2017;41:1454–1465PubMedCrossRef Wilson A, Ronnekleiv-Kelly SM, Pawlik TM. Regret in surgical decision making: a systematic review of patient and physician perspectives. World J Surg 2017;41:1454–1465PubMedCrossRef
2.
Zurück zum Zitat Robson N, Rew D. Collective wisdom and decision making in surgical oncology. Eur J Surg Oncol 2010;36:230–236PubMedCrossRef Robson N, Rew D. Collective wisdom and decision making in surgical oncology. Eur J Surg Oncol 2010;36:230–236PubMedCrossRef
3.
Zurück zum Zitat Lamb B, Green JS, Vincent C, et al. Decision making in surgical oncology. Surg Oncol 2011;20:163–8PubMedCrossRef Lamb B, Green JS, Vincent C, et al. Decision making in surgical oncology. Surg Oncol 2011;20:163–8PubMedCrossRef
5.
Zurück zum Zitat Nagasue N, Yukaya H, Hamada T, et al. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 1984;54:1461–1465PubMedCrossRef Nagasue N, Yukaya H, Hamada T, et al. The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 1984;54:1461–1465PubMedCrossRef
6.
Zurück zum Zitat Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–928PubMedCrossRef Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918–928PubMedCrossRef
7.
Zurück zum Zitat Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34PubMedCrossRef Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34PubMedCrossRef
8.
Zurück zum Zitat Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390PubMedCrossRef Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390PubMedCrossRef
9.
Zurück zum Zitat Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol 2015;33:1835–1844PubMedCrossRef Knox JJ, Cleary SP, Dawson LA. Localized and systemic approaches to treating hepatocellular carcinoma. J Clin Oncol 2015;33:1835–1844PubMedCrossRef
10.
Zurück zum Zitat Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156(477–491):e1 Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156(477–491):e1
11.
Zurück zum Zitat Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011;253:453–469PubMedCrossRef Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011;253:453–469PubMedCrossRef
12.
Zurück zum Zitat Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004;127:S248-S260PubMedCrossRef Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004;127:S248-S260PubMedCrossRef
13.
Zurück zum Zitat Liu J, Zhang H, Xia Y, et al. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2019;21:1–13CrossRef Liu J, Zhang H, Xia Y, et al. Impact of clinically significant portal hypertension on outcomes after partial hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2019;21:1–13CrossRef
14.
Zurück zum Zitat Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol 2020;72:75–84PubMedCrossRef Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol 2020;72:75–84PubMedCrossRef
15.
Zurück zum Zitat Vitale A, Burra P, Frigo AC, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol 2015;62:617–624PubMedCrossRef Vitale A, Burra P, Frigo AC, et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. J Hepatol 2015;62:617–624PubMedCrossRef
16.
Zurück zum Zitat Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61:583–588PubMedCrossRef Kokudo T, Hasegawa K, Yamamoto S, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61:583–588PubMedCrossRef
17.
Zurück zum Zitat Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137:403–10PubMedCrossRef Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137:403–10PubMedCrossRef
18.
Zurück zum Zitat Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 2016;65:938–943PubMedCrossRef Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 2016;65:938–943PubMedCrossRef
19.
Zurück zum Zitat Dhir M, Melin AA, Douaiher J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 2016;263:1112–1125PubMedCrossRef Dhir M, Melin AA, Douaiher J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 2016;263:1112–1125PubMedCrossRef
20.
Zurück zum Zitat Yang T, Lu JH, Lau WY, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a propensity score matching analysis. J Hepatol 2016;64:583–593PubMedCrossRef Yang T, Lu JH, Lau WY, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a propensity score matching analysis. J Hepatol 2016;64:583–593PubMedCrossRef
21.
Zurück zum Zitat Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg 2019;154:209–217PubMedCrossRef Xu XF, Xing H, Han J, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg 2019;154:209–217PubMedCrossRef
22.
Zurück zum Zitat Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. Br J Surg. 2019;106:1228–1236PubMedCrossRef Yang T, Liu K, Liu CF, et al. Impact of postoperative infective complications on long-term survival after liver resection for hepatocellular carcinoma. Br J Surg. 2019;106:1228–1236PubMedCrossRef
23.
Zurück zum Zitat Wang MD, Li C, Li J, et al. Long-term survival outcomes after liver resection for binodular hepatocellular carcinoma: a multicenter cohort study. Oncologist 2019;24:e730–e739PubMedPubMedCentralCrossRef Wang MD, Li C, Li J, et al. Long-term survival outcomes after liver resection for binodular hepatocellular carcinoma: a multicenter cohort study. Oncologist 2019;24:e730–e739PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol 2018;37:481–491PubMedCrossRef Tellapuri S, Sutphin PD, Beg MS, et al. Staging systems of hepatocellular carcinoma: a review. Indian J Gastroenterol 2018;37:481–491PubMedCrossRef
26.
27.
Zurück zum Zitat Kerr KF, Brown MD, Zhu K, et al. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol 2016;34:2534–40PubMedPubMedCentralCrossRef Kerr KF, Brown MD, Zhu K, et al. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol 2016;34:2534–40PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Dasari B, Hodson J, Sutcliffe RP, et al. Developing and validating a preoperative risk score to predict 90-day mortality after liver resection. J Surg Oncol 2019;119:472–478PubMedCrossRef Dasari B, Hodson J, Sutcliffe RP, et al. Developing and validating a preoperative risk score to predict 90-day mortality after liver resection. J Surg Oncol 2019;119:472–478PubMedCrossRef
29.
Zurück zum Zitat Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 2015;261:939–946PubMedCrossRef Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 2015;261:939–946PubMedCrossRef
30.
Zurück zum Zitat Yang P, Qiu J, Li J, et al. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg 2016;263:778–786PubMedCrossRef Yang P, Qiu J, Li J, et al. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Ann Surg 2016;263:778–786PubMedCrossRef
31.
Zurück zum Zitat Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020;72:215–229PubMedCrossRef Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol 2020;72:215–229PubMedCrossRef
32.
Zurück zum Zitat Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020 Qin S, Ren Z, Meng Z, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020
33.
Zurück zum Zitat Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006;141:191–8PubMedCrossRef Lai EC, Lau WY. Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 2006;141:191–8PubMedCrossRef
34.
Zurück zum Zitat Yang T, Sun YF, Zhang J, et al. Partial hepatectomy for ruptured hepatocellular carcinoma. Br J Surg 2013;100:1071–1079PubMedCrossRef Yang T, Sun YF, Zhang J, et al. Partial hepatectomy for ruptured hepatocellular carcinoma. Br J Surg 2013;100:1071–1079PubMedCrossRef
35.
Zurück zum Zitat Moris D, Chakedis J, Sun SH, et al. Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review. J Surg Oncol 2018;117:341–353PubMedCrossRef Moris D, Chakedis J, Sun SH, et al. Management, outcomes, and prognostic factors of ruptured hepatocellular carcinoma: a systematic review. J Surg Oncol 2018;117:341–353PubMedCrossRef
36.
Zurück zum Zitat Glantzounis GK, Tokidis E, Basourakos SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017;43:32–41PubMedCrossRef Glantzounis GK, Tokidis E, Basourakos SP, et al. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017;43:32–41PubMedCrossRef
37.
Zurück zum Zitat Song T. Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discov Ther. 2015;9:319–330PubMedCrossRef Song T. Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discov Ther. 2015;9:319–330PubMedCrossRef
38.
Zurück zum Zitat Raptis DA, Linecker M, Kambakamba P, et al. Defining benchmark outcomes for ALPPS. Ann Surg 2019;270:835–841PubMedCrossRef Raptis DA, Linecker M, Kambakamba P, et al. Defining benchmark outcomes for ALPPS. Ann Surg 2019;270:835–841PubMedCrossRef
39.
Zurück zum Zitat Olthof PB, Schnitzbauer AA, Schadde E. The HPB controversy of the decade: 2007–2017 - ten years of ALPPS. Eur J Surg Oncol 2018;44:1624–1627PubMedCrossRef Olthof PB, Schnitzbauer AA, Schadde E. The HPB controversy of the decade: 2007–2017 - ten years of ALPPS. Eur J Surg Oncol 2018;44:1624–1627PubMedCrossRef
40.
Zurück zum Zitat Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66:510–517PubMedCrossRef Kokudo T, Hasegawa K, Matsuyama Y, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66:510–517PubMedCrossRef
41.
Zurück zum Zitat Liang L, Chen TH, Li C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford) 2018;20:1119–1129CrossRef Liang L, Chen TH, Li C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford) 2018;20:1119–1129CrossRef
43.
Zurück zum Zitat Morris AM. Rational vs. intuitive judgment in surgical decision making. Ann Surg 2016;264:887–888PubMedCrossRef Morris AM. Rational vs. intuitive judgment in surgical decision making. Ann Surg 2016;264:887–888PubMedCrossRef
Metadaten
Titel
Development and validation of an individualized prediction calculator of postoperative mortality within 6 months after surgical resection for hepatocellular carcinoma: an international multicenter study
verfasst von
Lei Liang
Bing Quan
Han Wu
Yong-Kang Diao
Jie Li
Ting-Hao Chen
Yao-Ming Zhang
Ya-Hao Zhou
Wan-Guang Zhang
Hong Wang
Matteo Serenari
Matteo Cescon
Myron Schwartz
Yong-Yi Zeng
Ying-Jian Liang
Hang-Dong Jia
Hao Xing
Chao Li
Ming-Da Wang
Wen-Tao Yan
Wan-Yuan Chen
Wan Yee Lau
Cheng-Wu Zhang
Timothy M. Pawlik
Dong-Sheng Huang
Feng Shen
Tian Yang
Publikationsdatum
03.02.2021
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 2/2021
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10140-7

Weitere Artikel der Ausgabe 2/2021

Hepatology International 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.